Quarterly report pursuant to Section 13 or 15(d)

Notes Payable (Tables)

v2.4.0.8
Notes Payable (Tables)
 9 Months Ended
Sep. 30, 2014
Notes Payable  
Schedule of notes payable

 

 

 

September 30,
2014
(unaudited)

 

December 31,
2013

 

 

 

 

 

 

 

Revenue Interest Purchase Agreement with PDL BioPharma, Inc. (“PDL”) for aggregate of $20,800,000 with amounts payable monthly at 9.95% of Net Revenues through September 2014; and the greater of (i) 9.95% of product revenue or (ii) specific quarterly amounts varying from approximately $1.3 million to $2.5 million per quarter through September 2020. The minimum annual payment amounts are as follows: 2014 - $1,250,805, 2015 - $6,781,440, 2016 - $9,232,642, 2017 and 2018 - $9,000,000, 2019 - $9,063,000 and 2020 - $6,939,000.

 

$
28,173,877 

 

$
25,363,695 

 

Long-term Notes Payable

 

$
28,173,877 

 

$
25,363,695